← Back to All US Stocks

Tenon Medical, Inc. (TNONW) Stock Fundamental Analysis & AI Rating 2026

TNONW Nasdaq Surgical & Medical Instruments & Apparatus DE CIK: 0001560293
Recently Updated • Analysis: Apr 17, 2026 • SEC Data: 2025-12-31
STRONG SELL
85% Conf
Pending
Analysis scheduled

📊 TNONW Key Takeaways

Revenue: $3.9M
Net Margin: -318.4%
Free Cash Flow: $-11.0M
Current Ratio: 2.11x
Debt/Equity: 0.00x
EPS: $-1.70
AI Rating: STRONG SELL with 85% confidence
Tenon Medical, Inc. (TNONW) receives a STRONG SELL rating with 85% confidence from our AI fundamental analysis based on SEC 10-K filings. With revenue of $3.9M, net profit margin of -318.4%, and return on equity (ROE) of -249.1%, Tenon Medical, Inc. demonstrates mixed fundamentals in the Healthcare sector. Below is our complete TNONW stock analysis for 2026.

Is Tenon Medical, Inc. (TNONW) a Good Investment?

Claude

Tenon Medical is an early-stage surgical device company with promising 20.4% revenue growth and healthy 59.8% gross margins, indicating product-market fit. However, the company is burning $10.7M annually in operating cash flow against only $3.9M in revenue, with approximately 4 months of cash runway at current burn rates. Without rapid revenue acceleration, significant cost reduction, or emergency financing, the company faces severe solvency risk.

Why Buy Tenon Medical, Inc. Stock? TNONW Key Strengths

Claude
  • + Strong gross margin of 59.8% indicates strong product value and pricing power
  • + Revenue growing 20.4% YoY demonstrates market demand for surgical devices
  • + Debt-free balance sheet with no long-term debt obligations
  • + Adequate short-term liquidity with 2.11x current ratio and 1.78x quick ratio
  • + Net loss improving 8.2% YoY shows operational efficiency gains

TNONW Stock Risks: Tenon Medical, Inc. Investment Risks

Claude
  • ! Severe cash burn of $10.7M annually against $3.9M revenue creates ~4 month runway with current $3.8M cash reserves
  • ! Operating margin of -324.3% indicates operating expenses 13x revenue, unsustainable even for early-stage companies
  • ! Free cash flow of -$11.0M compounds liquidity crisis and limits ability to fund operations without external capital
  • ! Negative ROE (-249.1%) and ROA (-116.7%) indicate extremely poor capital efficiency and asset utilization
  • ! High dilution risk from required future financing at distressed valuations

Key Metrics to Watch

Claude
  • * Quarterly revenue trajectory and acceleration toward gross profit breakeven
  • * Operating cash burn rate and monthly cash consumption trends
  • * Gross margin sustainability as volume scales
  • * Cash balance depletion timeline and financing announcements
  • * Operating expense reduction or revenue inflection required for survival

Tenon Medical, Inc. (TNONW) Financial Metrics & Key Ratios

Revenue
$3.9M
Net Income
$-12.6M
EPS (Diluted)
$-1.70
Free Cash Flow
$-11.0M
Total Assets
$10.8M
Cash Position
$3.8M

💡 AI Analyst Insight

Strong liquidity with a 2.11x current ratio provides a solid financial cushion.

TNONW Profit Margin, ROE & Profitability Analysis

Gross Margin 59.8%
Operating Margin -324.3%
Net Margin -318.4%
ROE -249.1%
ROA -116.7%
FCF Margin -279.4%

TNONW vs Healthcare Sector: How Tenon Medical, Inc. Compares

How Tenon Medical, Inc. compares to Healthcare sector averages

Net Margin
TNONW -318.4%
vs
Sector Avg 12.0%
TNONW Sector
ROE
TNONW -249.1%
vs
Sector Avg 15.0%
TNONW Sector
Current Ratio
TNONW 2.1x
vs
Sector Avg 2.0x
TNONW Sector
Debt/Equity
TNONW 0.0x
vs
Sector Avg 0.6x
TNONW Sector

Sector benchmarks are approximate industry averages. Actual sector performance may vary.

Is Tenon Medical, Inc. Stock Overvalued? TNONW Valuation Analysis 2026

Based on fundamental analysis, Tenon Medical, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.

Return on Equity
-249.1%
Sector avg: 15%
Net Profit Margin
-318.4%
Sector avg: 12%
Revenue Growth
N/A
Year-over-year
Debt/Equity
0.00x
Sector avg: 0.6x

Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.

Tenon Medical, Inc. Balance Sheet: TNONW Debt, Cash & Liquidity

Current Ratio
2.11x
Quick Ratio
1.78x
Debt/Equity
0.00x
Debt/Assets
53.2%
Interest Coverage
-376.24x
Long-term Debt
N/A

TNONW Revenue & Earnings Growth: 5-Year Financial Trend

TNONW 5-year financial data: Year 2022: Revenue $691.0K, Net Income -$7.0M, EPS $-7.81. Year 2023: Revenue $2.9M, Net Income -$18.9M, EPS $-23.62. Year 2024: Revenue $3.3M, Net Income -$15.6M, EPS $-68.64. Year 2025: Revenue $3.9M, Net Income -$13.7M, EPS $-11.26.
Revenue
Net Income
EPS (right axis)

5-Year Trend Summary: Tenon Medical, Inc.'s revenue has grown significantly by 471% over the 5-year period, indicating strong business expansion. The most recent EPS of $-11.26 indicates the company is currently unprofitable.

TNONW Revenue Growth, EPS Growth & YoY Performance

Revenue Growth
N/A
Year-over-year
Net Income Growth
N/A
Year-over-year
EPS Growth
N/A
Earnings per share
FCF Margin
-279.4%
Free cash flow / Revenue

TNONW Quarterly Earnings & Performance

Quarterly financial performance data for Tenon Medical, Inc. including revenue, net income, and earnings per share.
Quarter Revenue Net Income EPS
Q3 2025 $887.0K -$3.2M $-0.40
Q2 2025 $564.0K -$2.8M $-0.36
Q1 2025 $719.0K -$3.6M $-1.01
Q3 2024 $887.0K -$3.2M $-3.63
Q2 2024 $743.0K -$3.8M $-1.02
Q1 2024 $433.0K -$3.6M $-1.25
Q3 2023 $208.0K -$3.2M $-1.46
Q2 2023 $135.0K -$4.3M $-0.33

Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.

Tenon Medical, Inc. Dividends, Buybacks & Capital Allocation

Operating Cash Flow
-$10.7M
Cash generated from operations
Capital Expenditures
$273.0K
Investment in assets
Dividends
None
No dividend program

TNONW SEC Filings: Latest 10-K & 10-Q Analysis

Access official SEC EDGAR filings for Tenon Medical, Inc. (CIK: 0001560293)

📋 Recent SEC Filings

Date Form Document Action
Mar 27, 2026 10-K ea0280493-10k_tenon.htm View →
Mar 19, 2026 8-K ea0282552-8k_tenon.htm View →
Mar 17, 2026 8-K ea0281937-8k_tenon.htm View →
Mar 5, 2026 4 xslF345X05/ownership.xml View →
Feb 27, 2026 8-K ea0279079-8k_tenon.htm View →

Frequently Asked Questions about TNONW

What is the AI rating for TNONW?

Tenon Medical, Inc. (TNONW) has an AI rating of STRONG SELL with 85% confidence, based on fundamental analysis of SEC EDGAR filings.

What are TNONW's key strengths?

Claude: Strong gross margin of 59.8% indicates strong product value and pricing power. Revenue growing 20.4% YoY demonstrates market demand for surgical devices.

What are the risks of investing in TNONW?

Claude: Severe cash burn of $10.7M annually against $3.9M revenue creates ~4 month runway with current $3.8M cash reserves. Operating margin of -324.3% indicates operating expenses 13x revenue, unsustainable even for early-stage companies.

What is TNONW's revenue and growth?

Tenon Medical, Inc. reported revenue of $3.9M.

Does TNONW pay dividends?

Tenon Medical, Inc. does not currently pay dividends.

Where can I find TNONW SEC filings?

Official SEC filings for Tenon Medical, Inc. (CIK: 0001560293) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.

What is TNONW's EPS?

Tenon Medical, Inc. has a diluted EPS of $-1.70.

How is the AI analysis conducted?

Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.

Is TNONW a good stock to buy right now?

Based on our AI fundamental analysis in April 2026, Tenon Medical, Inc. has a STRONG SELL rating with 85% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.

Is TNONW stock overvalued or undervalued?

Valuation metrics for TNONW: ROE of -249.1% (sector avg: 15%), net margin of -318.4% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.

Should I buy TNONW stock in 2026?

Our dual AI analysis gives Tenon Medical, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.

What is TNONW's free cash flow?

Tenon Medical, Inc.'s operating cash flow is $-10.7M, with capital expenditures of $273.0K. FCF margin is -279.4%.

How does TNONW compare to other Healthcare stocks?

Vs Healthcare sector averages: Net margin -318.4% (avg: 12%), ROE -249.1% (avg: 15%), current ratio 2.11 (avg: 2).

Top Rated Stocks
NSSC 92% MLI 92% MELI 92% MDXG 92% MANH 92% INVA 92% GGG 92% GCT 92% FTNT 92% FSLR 92%
Sector: All Healthcare Stocks →
Disclaimer: This analysis is generated by Claude AI (Anthropic) and ChatGPT (OpenAI) based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: Apr 17, 2026 | Data as of: 2025-12-31 | Powered by Claude AI